Baird raised the firm’s price target on LivaNova to $66 from $58 and keeps a Neutral rating on the shares. The firm sees upside potential to its 2024-2025 revenue/EPS outlook, especially as Essenz gains traction, capacity expansion potentially helps 2H24/2025 oxygenator growth, and operational growth/leverage takes hold.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIVN:
- LivaNova Refocuses Structure, Integrates Circulatory Support
- LivaNova raises FY24 adjusted EPS view to $3.05-$3.15 from $2.95-$3.05
- LivaNova reports Q1 adjusted EPS 73c, consensus 49c
- LivaNova announces Ahmet Tezel as chief innovation officer
- LivaNova jumps nearly 12% after saying trial likely to meet primary endpoint